Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 14/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CDK4 | P11802 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22310620 | 1.00 | CDK2 (1.00) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL22311799 | 1.00 | CDK2 (1.00) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL29148605 | 0.92 | CDK2 (1.00) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL30679393 | 0.92 | CDK2 (1.00) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL24585229 | 0.89 | CDK2 (0.81) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL24586144 | 0.89 | CDK2 (0.81) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL24586251 | 0.89 | CDK2 (0.81) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL24586153 | 0.89 | CDK2 (0.81) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL24586249 | 0.89 | CDK2 (0.81) | CDK2CCNE1GSK3BCDK1CDK4 | |
| SCHEMBL24586157 | 0.89 | CDK2 (0.81) | CDK2CCNE1GSK3BCDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154426-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |